Steven Cohen Viking Therapeutics, Inc. Call Options Transaction History
Point72 Asset Management, L.P.
- $39.3 Billion
- Q1 2024
Call Options
1 transactions
Others Institutions Holding VKTX
# of Institutions
426Shares Held
63.1MCall Options Held
7.39MPut Options Held
5.13M-
Black Rock Inc. New York, NY8.27MShares$426 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.79MShares$401 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.59MShares$185 Million3.55% of portfolio
-
State Street Corp Boston, MA3.33MShares$171 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.33MShares$120 Million0.02% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $3.95B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...